OncoMatch/Clinical Trials/NCT05749588
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Is NCT05749588 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for triple-negative breast cancer.
Treatment: A1: SHR-A1811 · A2: SHR-A1811 with Camrelizumab · B1: TROP2 ADC · B2: TROP2 ADC with Camrelizumab · C1: SHR-A1811 · C2: SHR-A1811 with BP102 · D1: TROP2 ADC · D2: TROP2 ADC with BP102 · E1: SHR-A1811 · F1: TROP2 ADC · G1: SHR-A1811 · H1: TROP2 ADC — This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: ESR1 negative (<1% positive tumor cells by immunohistochemistry) (<1% positive tumor cells by immunohistochemistry)
ER <1% positive tumor cells by immunohistochemistry are defined as ER negative
Required: PR (PGR) negative (<1% positive tumor cells by immunohistochemistry) (<1% positive tumor cells by immunohistochemistry)
PR <1% positive tumor cells are defined as PR negative
Required: HER2 (ERBB2) negative (0-1+ or 2+ but negative by FISH without amplification) (0-1+ or 2+ but negative by FISH without amplification)
HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negative
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
HB ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5 x 10^9 /L; PLT ≥75 x 10^9 /L
Kidney function
Serum Cr ≤1×ULN, endogenous creatinine clearance > 50 ml/min (Cockcroft-Gault formula)
Liver function
TBIL ≤1.5×ULN; ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN
The functions of the main organs are basically normal and meet the following conditions: ... see above
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05749588 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 negative (<1% positive tumor cells by immunohistochemistry) is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR negative (<1% positive tumor cells by immunohistochemistry) is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative (0-1+ or 2+ but negative by FISH without amplification) is a required biomarker for enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify